Current psychiatry reports · 2026
Effects of Pharmacological and Psychological Treatments on Depressive Symptoms in Body Dysmorphic Disorder: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Loewen Alvaro, Peñuelas-Calvo Inmaculada, Alacreu-Crespo Adrián, Jiménez-Muñoz Laura, Grijalba-Chiva Sandra, Mata-Iturralde Laura, Porras-Segovia Alejandro
Аннотация
PURPOSE OF REVIEW: This systematic review and meta-analysis evaluated the effects of pharmacological and psychological treatments on depressive symptoms in individuals with body dysmorphic disorder (BDD). The primary objective was to assess treatment-related changes in depressive symptom severity among patients with BDD, while evidence regarding dysmorphic symptoms and combined interventions was reviewed narratively and should be interpreted with caution.
RECENT FINDINGS: Across 46 studies (N = 2,227), evidence suggests antidepressants-especially SSRIs-substantially reduce depressive symptoms. Cognitive-behavioral therapy (CBT) also shows large effects, though variability across trials remains high. Most research includes small samples and heterogeneous designs, underscoring the need for consistency. Pharmacological treatment yielded a pooled standardized mean difference (SMD) of -0.96 (95% CI [-1.37,-0.54], p < 0.001), with SSRIs showing the greatest improvement (SMD =-1.16). CBT demonstrated comparable efficacy (SMD = -1.12), remaining significant after bias correction (SMD = -0.65). Combined approaches may provide optimal outcomes. Future research should focus on large, standardized RCTs evaluating functional recovery and suicide risk reduction.
RECENT FINDINGS: Across 46 studies (N = 2,227), evidence suggests antidepressants-especially SSRIs-substantially reduce depressive symptoms. Cognitive-behavioral therapy (CBT) also shows large effects, though variability across trials remains high. Most research includes small samples and heterogeneous designs, underscoring the need for consistency. Pharmacological treatment yielded a pooled standardized mean difference (SMD) of -0.96 (95% CI [-1.37,-0.54], p < 0.001), with SSRIs showing the greatest improvement (SMD =-1.16). CBT demonstrated comparable efficacy (SMD = -1.12), remaining significant after bias correction (SMD = -0.65). Combined approaches may provide optimal outcomes. Future research should focus on large, standardized RCTs evaluating functional recovery and suicide risk reduction.